Moderna Posts Q2 Loss, Norovirus Vaccine Fails Phase 3 Interim; Cash Burn Accelerates
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna's Q2 loss of $1.97/share beat estimates, but the real story is the norovirus vaccine candidate mRNA-1403 failing its Phase 3 interim analysis, forcing an additional cohort enrollment and delaying the program. Revenue of $145M topped consensus, yet cash burn remains severe—$6.9B on hand as of June 30, down from $7.5B in March, with a further $950M litigation payment made in July. R&D spending fell 7% YoY to $651M as late-stage programs wound down, but the norovirus setback raises pipeline risk. The company reaffirmed 2026 sales guidance of $2.138B, with 55% of H2 revenue expected in Q3. The August 5 PDUFA date for flu vaccine mFLUSIVA is now a critical catalyst—approval could offset some negative sentiment, but the norovirus failure and cash trajectory keep pressure on the stock, which fell another 2.7% today after a 7.2% premarket drop.
At the time of this announcement, MRNA was trading at $56.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.6B. The 52-week trading range was $22.28 to $85.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.